Literature DB >> 1856147

Pharmacokinetic evaluation of single daily dose amikacin.

P Van der Auwera1.   

Abstract

The pharmacokinetic parameters of amikacin given once daily were compared to those of amikacin given bd at different daily dosages. In adult patients, 'peak' serum concentrations (30 min after 30 min infusion) were linearly proportional to the dose given with the following equation:-'peak' = 4.23 (dose in mg/kg)-3.93 (r, 0.827; P less than 0.0001). Areas under curves were also proportional to the dose and were not affected by the schedule of administration (od or bd). Serum half-life was neither affected by the dose nor the schedule of administration. However, the half-life was approximately 3 h in adult patients with infections and was greater than 4 h in elderly patients. In multiple dose studies, no accumulation was observed either in children or adults. However, 'peak' serum concentrations increased slightly. New recommendations for therapeutic drug monitoring need to be formulated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856147     DOI: 10.1093/jac/27.suppl_c.63

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; E Tassin; G A Loeuille; A Deschildre; D Druon; J C Elian; C Arrouet-Lagandre; J P Farriaux
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

2.  Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

Authors:  Jin Lee; Nicole Ammerman; Anusha Agarwal; Maram Naji; Si-Yang Li; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

Authors:  D J Demczar; A N Nafziger; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Authors:  Yuanyuan Jiao; Bartolome Moya; Mong-Jen Chen; Alexandre P Zavascki; Hsinyin Tsai; Xun Tao; Dhruvitkumar S Sutaria; Arnold Louie; John D Boyce; Deanna Deveson Lucas; Tae Hwan Kim; Brian T Tsuji; Robert A Bonomo; George L Drusano; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Population pharmacokinetics of amikacin in critically ill patients.

Authors:  F Bressolle; A Gouby; J M Martinez; P Joubert; G Saissi; R Guillaud; R Gomeni
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

6.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; V Launay; G A Loeuille; A Sardet; A Deschildre; D Druon; C Arrouet-Lagande
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

7.  Aminoglycoside dosages and nephrotoxicity: quantitative relationships.

Authors:  Florent Rougier; Michel Ducher; Michel Maurin; Stéphane Corvaisier; Daniel Claude; Roger Jelliffe; Pascal Maire
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Once daily antibiotic regimen in paediatric oncology.

Authors:  E Bouffet; C Fuhrmann; D Frappaz; D Couillioud; V Artiges; C Charra; D Bouhour; M Brunat Mentigny
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

9.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen.

Authors:  P Joubert; F Bressolle; A Gouby; P Y Douçot; G Saissi; R Gomeni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.